Related Articles

• suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion
• Soluble urokinase‑type plasminogen activator receptor and urokinase‑type plasminogen activator receptor contribute to chemoresistance in leukemia
• Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality
• Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer.
• Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis